Immunotherapy of type 1 diabetes: where are we and where should we be going?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Immunity

• Publication date

  2010-04-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.immuni.2010.04.002PMID 20412759PMCID PMC2860878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

  2010cited by this paper
• A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice

  2010cited by this paper
• Dimorphic histopathology of long-standing childhood-onset diabetes

  2010cited by this paper
• Genetics of type 1A diabetes.

  2009cited by this paper
• Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

  2009cited by this paper
• Etanercept Treatment in Children With New-Onset Type 1 Diabetes

  2009cited by this paper
• Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot Randomized, Placebo-Controlled, Double-Blind Study

  2009cited by this paper
• Diabetes: A virus–gene collaboration

  2009cited by this paper
• Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes

  2009cited by this paper
• Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal

  2009cited by this paper
• Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

  2009cited by this paper
• C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

  2009cited by this paper
• Prevention of type 1 diabetes: the time has come

  2008influential reference
• Murine Antithymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time-Dependent Induction of Immunoregulation

  2008cited by this paper
• ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms

  2008influential reference
• Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

  2008cited by this paper
• GAD treatment and insulin secretion in recent-onset type 1 diabetes.

  2008cited by this paper
• The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus

  2008cited by this paper
• Translating mucosal antigen based prevention of autoimmune diabetes to human.

  2008cited by this paper
• Polyclonal Adaptive Regulatory CD4 Cells That Can Reverse Type I Diabetes Become Oligoclonal Long-Term Protective Memory Cells1

  2008cited by this paper
• Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice

  2008cited by this paper
• A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

  2008cited by this paper
• B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in FcγR Effector Functions1

  2008cited by this paper
• Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice

  2008cited by this paper
• Genetic and therapeutic control of diabetogenic CD8+ T cells.

  2008cited by this paper
• A Th1-Recognized Peptide P277, When Tandemly Repeated, Enhances a Th2 Immune Response toward Effective Vaccines against Autoimmune Diabetes in Nonobese Diabetic Mice1

  2008cited by this paper
• Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

  2008cited by this paper
• Effect of heat shock protein peptide DiaPep277 on ß‐cell function in paediatric and adult patients with recent‐onset diabetes mellitus type 1: two prospective, randomized, double‐blind phase II trials

  2007cited by this paper
• Heat‐shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double‐blind phase II study

  2007cited by this paper
• Therapy with the hsp60 peptide DiaPep277™ in C‐peptide positive type 1 diabetes patients

  2007cited by this paper
• Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

  2007cited by this paper
• Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

  2007cited by this paper
• Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells.

  2007cited by this paper
• Mucosal exposure to antigen: Cause or cure of type 1 diabetes?

  2007cited by this paper
• Dendritic cells with TGF-β1 differentiate naïve CD4+CD25− T cells into islet-protective Foxp3+ regulatory T cells

  2007cited by this paper
• Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease

  2007influential reference
• Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

  2007cited by this paper
• Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients

  2007cited by this paper
• Peripheral Tolerance Induction Using Ethylenecarbodiimide-Fixed APCs Uses both Direct and Indirect Mechanisms of Antigen Presentation for Prevention of Experimental Autoimmune Encephalomyelitis1

  2007cited by this paper
• Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes.

  2006cited by this paper
• Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

  2006cited by this paper
• Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway

  2006cited by this paper
• Adaptive Islet-Specific Regulatory CD4 T Cells Control Autoimmune Diabetes and Mediate the Disappearance of Pathogenic Th1 Cells In Vivo1

  2006cited by this paper
• Intranasal Vaccination with Proinsulin DNA Induces Regulatory CD4+ T Cells That Prevent Experimental Autoimmune Diabetes1

  2006cited by this paper
• Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

  2006cited by this paper
• Effects of Autoimmunity and Immune Therapy on β-Cell Turnover in Type 1 Diabetes

  2006cited by this paper
• Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis.

  2006cited by this paper
• Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes

  2006cited by this paper
• Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

  2006cited by this paper
• Peptide‐Pulsed Immature Dendritic Cells Reduce Response to β Cell Target Antigens and Protect NOD Recipients from Type I Diabetes

  2006cited by this paper
• A comprehensive review of interventions in the NOD mouse and implications for translation.

  2005cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope

  2005cited by this paper
• Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice

  2005cited by this paper
• Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1

  2005cited by this paper
• Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

  2005cited by this paper
• Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide

  2005cited by this paper
• Oral tolerance

  2005cited by this paper
• Predicting type 1 diabetes

  2005cited by this paper
• The NOD mouse: a model of immune dysregulation.

  2005cited by this paper
• Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes

  2005cited by this paper
• Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.

  2005cited by this paper
• TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

  2005cited by this paper
• Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.

  2005influential reference
• Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes

  2004cited by this paper
• T Cells , Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide , Suppress Autoimmune Diabetes

  2004cited by this paper
• IL-1 receptor deficiency slows progression to diabetes in the NOD mouse.

  2004cited by this paper
• European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.

  2004cited by this paper
• In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes

  2004cited by this paper
• Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.

  2004cited by this paper
• C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

  2004cited by this paper
• Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

  2004cited by this paper
• Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.

  2004cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

  2003cited by this paper
• CD3-specific antibody-induced active tolerance: from bench to bedside

  2003cited by this paper
• Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

  2003cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

  2003cited by this paper
• TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

  2003cited by this paper
• Nasal administration of CTB‐insulin induces active tolerance against autoimmune diabetes in non‐obese diabetic (NOD) mice

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

  2001cited by this paper
• Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

  2001cited by this paper
• β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

  2001cited by this paper
• Suppressor T cells – they’re back and critical for regulation of autoimmunity!

  2001cited by this paper
• Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes1

  2001cited by this paper
• Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

  2000cited by this paper
• Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial

  2000influential reference
• No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)

  2000cited by this paper
• Pathologic Role and Temporal Appearance of Newly Emerging Autoepitopes in Relapsing Experimental Autoimmune Encephalomyelitis1

  2000cited by this paper
• Oral tolerance.

  2000cited by this paper
• Nicotinamide prevents the development of diabetes in the cyclophosphamide‐induced NOD mouse model by reducing beta‐cell apoptosis

  2000cited by this paper
• In vitro characterization of five humanized OKT3 effector function variant antibodies.

  2000cited by this paper
• Nicotinamide in type 1 diabetes. Mechanism of action revisited.

  1999cited by this paper
• The NOD mouse model of type 1 diabetes: As good as it gets?

  1999cited by this paper
• Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes

  1999cited by this paper
• Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.

  1998cited by this paper
• Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice.

  1998cited by this paper

• Therapeutic potential of anti-thymocyte globulin in type 1 diabetes: A systematic review

  2025cites this paper
• TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes

  2024cites this paper
• Mechanism of Action of Oral Salmonella-Based Vaccine to Prevent and Reverse Type 1 Diabetes in NOD Mice

  2024cites this paper
• Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation.

  2024cites this paper
• Stem cells therapy for diabetes: from past to future.

  2023cites this paper
• Magnetic Particle Imaging of Transplanted Human Islets Using a Machine Learning Algorithm.

  2023cites this paper
• Liver-Targeting Nanoplatforms for the Induction of Immune Tolerance

  2023cites this paper
• Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes

  2022cites this paper
• Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice

  2022cites this paper
• In vitro-derived insulin-producing cells modulate Th1 immune responses and induce IL-10 in streptozotocin-induced mouse model of pancreatic insulitis.

  2021cites this paper
• Enhancing Antigen Presentation and Inducing Antigen-Specific Immune Tolerance with Amphiphilic Peptides

  2021cites this paper
• Restoring immunological tolerance in established experimental arthritis by combinatorial citrullinated peptides and immunomodulatory signals

  2021cites this paper
• Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes

  2021cites this paper
• A Patient with Atezolizumab-Induced Autoimmune Diabetes Mellitus Presenting with Diabetic Ketoacidosis

  2021cites this paper
• Current advances in Diabetes Type 1 and type 2 treatment: an overview

  2020cites this paper
• Encapsulated in Polyphenolic Microcapsules Dampening Antigen-Specific T Cell Responses with Antigens

  2020cites this paper
• Dampening Antigen-Specific T Cell Responses with Antigens Encapsulated in Polyphenolic Microcapsules

  2020cites this paper
• CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes

  2020cites this paper
• A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes.

  2019cites this paper
• Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2

  2019cites this paper
• Current Status on Immunological Therapies for Type 1 Diabetes Mellitus

  2019cites this paper
• Interleukin‐35 in immune‐related diseases: protection or destruction

  2019cites this paper
• Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis

  2018cites this paper
• Co‐delivery of siAlox15 and sunitinib for reversing the new‐onset of type 1 diabetes in non‐obese diabetic mice

  2018cites this paper
• Tolerogenic Iron Oxide Nanoparticles in Type 1 Diabetes: Biodistribution and Pharmacokinetics Studies in Nonobese Diabetic Mice.

  2018cites this paper
• Gene therapy and type 1 diabetes mellitus.

  2018cites this paper
• 41 – Noninfectious Disease Vaccines

  2018cites this paper
• Anti-TCRbmAb inCombinationWithNeurogenin3Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice

  2017cites this paper
• An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy.

  2017cites this paper
• Tolerogenic Nanoparticles to Treat Islet Autoimmunity

  2017cites this paper
• Multipeptide-coupled nanoparticles induce tolerance in ‘humanised’ HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes

  2017cites this paper
• Anti‐TCR&bgr; mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice

  2017cites this paper
• Understanding Autoimmune Diabetes through the Prism of the Tri-Molecular Complex

  2017cites this paper
• 1 Autoimmunity and Immunotherapy of Type 1 Diabetes

  2017influential citation
• Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.

  2017cites this paper
• 10 Tolerance and Autoimmunity in Type 1 Diabetes

  2017cites this paper
• A new approach for treatment of type 1 diabetes: Phytotherapy and phytopharmacology of regulatory T cells

  2017cites this paper
• Identification of Candidate Tolerogenic CD8+ T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model

  2016cites this paper
• Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option

  2016cites this paper
• Pep19 drives epitope spreading in periodontitis and periodontitis-associated autoimmune diseases.

  2016cites this paper
• Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model

  2016cites this paper
• Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes

  2016cites this paper
• Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice.

  2016cites this paper
• Proteomic Analysis of Disease Stratified Human Pancreas Tissue Indicates Unique Signature of Type 1 Diabetes

  2015cites this paper
• Distinct Roles of β-Cell Mass and Function During Type 1 Diabetes Onset and Remission

  2015cites this paper
• Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy

  2015cites this paper
• Less Is More: The Detrimental Consequences of Immunosuppressive Therapy in the Treatment of Type-1 Diabetes

  2015cites this paper
• Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes

  2015cites this paper
• The intravenous injection of oxidized LDL- or Apolipoprotein B100--Coupled splenocytes promotes Th1 polarization in wildtype and Apolipoprotein E--Deficient mice.

  2015cites this paper
• Immunotherapies currently in development for the treatment of type 1 diabetes

  2015cites this paper
• Small-Molecule Probes for the Modulation of Ligand-Receptor Interactions within the TNF Superfamily

  2015cites this paper
• Type 1 Diabetes Mellitus: Immune Modulation as a Prerequisite for Successful Gene Therapy Strategies

  2015cites this paper
• [Genetic and molecular background in autoimmune diabetes mellitus].

  2015cites this paper
• Bruton’s tyrosine kinase in chronic inflammation: from pathophysiology to therapy

  2015cites this paper
• Flowcytometric assessment of lymphocyte subsets in type-1 diabetic patients following allotransplantation of liver-derived fetal stem-cells.

  2015cites this paper
• Islet-associated T-cell receptor-β CDR sequence repertoire in prediabetic NOD mice reveals antigen-driven T-cell expansion and shared usage of VβJβ TCR chains.

  2015cites this paper
• Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a "humanized" transgenic mouse model of type 1 diabetes.

  2014cites this paper
• Oral Administration of Recombinant Lactococcus lactis Expressing HSP65 and Tandemly Repeated P277 Reduces the Incidence of Type I Diabetes in Non-Obese Diabetic Mice

  2014cites this paper
• Liposomal alpha-galactosylceramide plus insulin effects on type 1 diabetes in non-obese diabetic mice

  2014cites this paper
• Antigen-specific therapy against type 1 diabetes: mechanisms and perspectives.

  2014cites this paper
• Original hypothesis: Extracorporeal shockwaves as a homeostatic autoimmune restorative treatment (HART) for Type 1 diabetes mellitus.

  2014cites this paper
• Treg Vaccination in Autoimmune Type 1 Diabetes

  2014cites this paper
• An overview of non-insulin adjunctive therapies for Type 1 diabetes

  2014cites this paper
• Regulatory T cells control diabetes without compromising acute anti-viral defense.

  2014cites this paper
• Selective immunotargeting of diabetogenic CD4 T cells by genetically redirected T cells

  2014cites this paper
• A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease

  2014cites this paper
• PLG Scaffold Delivered Antigen-Specific Regulatory T Cells Induce Systemic Tolerance in Autoimmune Diabetes

  2013cites this paper
• A Missing PD-L1/PD-1 Coinhibition Regulates Diabetes Induction by Preproinsulin-Specific CD8 T-Cells in an Epitope-Specific Manner

  2013cites this paper
• Mechanistic basis of immunotherapies for type 1 diabetes mellitus.

  2013cites this paper
• Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto’s thyroiditis successfully treated with etanercept

  2013cites this paper
• Recovery From Overt Type 1 Diabetes Ensues When Immune Tolerance and β-Cell Formation Are Coupled With Regeneration of Endothelial Cells in the Pancreatic Islets

  2013cites this paper
• DNA Immunotherapies for Type 1 Diabetes

  2013cites this paper
• DIABETIC STUDIES The Review of Immunotherapy in Autoimmune Type 1 Diabetes

  2013cites this paper
• Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

  2013cites this paper
• Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

  2013cites this paper
• DIABETIC STUDIES The Review of Chapter III . 3 Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes

  2013cites this paper
• Insulin and type 1 diabetes: immune connections.

  2013cites this paper
• Etude de la réponse lymphocytaire T dans l’allergie de l’enfant, au diagnostic et au cours de la désensibilisation

  2013cites this paper
• DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8 + T cells independently of PD-1 and PD-L1

  2013cites this paper
• DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.

  2013cites this paper
• Carbon monoxide‐treated dendritic cells decrease β1‐integrin induction on CD8+ T cells and protect from type 1 diabetes

  2013cites this paper
• Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice

  2012cites this paper
• Diseases and Clinical Applications that Can Benefit from Long Lasting Implants and Injections

  2012cites this paper
• Immunotherapy in autoimmune type 1 diabetes.

  2012cites this paper
• Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.

  2012cites this paper
• Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination With Anti-CD3

  2012cites this paper
• GPS-MBA: Computational Analysis of MHC Class II Epitopes in Type 1 Diabetes

  2012cites this paper
• Surrogate insulin-producing cells

  2012cites this paper
• Improved vaccines through targeted manipulation of the body's immunological risk‐assessment?

  2012cites this paper
• Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

  2012influential citation
• Genetic Determination and Immunopathogenesis of Type 1 Diabetes Mellitus in Humans

  2012cites this paper
• Generation of T regulatory cells in children with newly diagnosed type 1 diabetes mellitus.

  2012cites this paper
• Chemokine-mediated modulation of autoimmunity in type 1 diabetes

  2012cites this paper
• Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

  2012cites this paper
• The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes

  2012cites this paper
• Treg Vaccination with a Strong-Agonistic Insulin Mimetope

  2012cites this paper
• Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures

  2012cites this paper
• Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

  2012cites this paper
• Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

  2012cites this paper
• Prevention of Autoimmune Diabetes by Ectopic Pancreatic β-Cell Expression of Interleukin-35

  2012cites this paper